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Abstract
Background: The ageing of the population is expected to bring an enormous growth in demand
for oncological health care. In order to anticipate and respond to future trends, cancer care needs
to be critically evaluated. The present study explores the possibility of conducting representative
and population-based research on cancer care on the basis of data drawn from the Cancer Registry.
Methods: A population-based state-wide cohort study (OVIS) has been carried out in Schleswig-
Holstein, Germany. All patients with malignant melanoma, breast, or prostate cancer were
identified in the Cancer Registry. Epidemiological data were obtained for all the patients and
screened for study eligibility. A postal questionnaire requesting information on diagnosis, therapy,
QoL and aftercare was sent to eligible patients.
Results: A total of 11,489 persons diagnosed with the cancer types of interest in the period from
January 2002 to July 2004 were registered in the Cancer Registry. Of the 5,354 (47%) patients who
gave consent for research, 4,285 (80% of consenters) completed the questionnaire. In terms of
relevant epidemiological variables, participants with melanoma were not found to be different from
non-participants with the same diagnosis. However, participants with breast or prostate cancer
were slightly younger and had smaller tumours than patients who did not participate in our study.
Conclusion: Population-based cancer registry data proved to be an invaluable resource for both
patient recruitment and non-participant analysis. It can help improve our understanding of the
strength and nature of differences between participants and non-respondents. Despite minor
differences observed in breast and prostate cancer, the OVIS-sample seems to represent the
source population adequately.
Introduction
Cancer diseases are the second most common cause of
death in Germany after cardiovascular diseases, with over
400,000 new cases of cancer diagnosed each year [1]. Ris-
ing incidence of cancer is partly due to the ageing popula-
tion and age-dependency of cancer incidence [2]. At the
same time, survival rate continues to improve for most
cancer types [3]. The expected increase in the overall prev-
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alence of cancer will soon require substantially more
resources for treatment services of cancer patients. To
respond to changing demand for oncological procedures,
a systematic investigation of cancer care is indicated. Stud-
ies from the USA report great differences in the access to
and the quality of health care services existing between
patient groups, regions, and health care providers [4-13].
Research from Europe suggests differences in tumour
stage at the time of diagnosis [14,15], in demand, quality
and adequacy of oncological care [16-20].
The OVIS-study (Onkologische Versorgung In Schleswig-
Holstein) is a state-wide research project aimed to exam-
ine possible differences in health care in patients with
malignant melanoma, breast or prostate cancer from the
patient's perspective. Schleswig-Holstein is the northern-
most state of Germany with a population of about 2.8
million and only a marginal difference in age structure as
compared to the whole of Germany. The study began in
November 2002; the recruitment ended in April 2005.
The aims of the study were:
- to collect and present data on medical care (diagnosis,
therapy, rehabilitation, aftercare) in patients with malig-
nant neoplasm of breast or prostate and malignant
melanoma of the skin who reside in Schleswig-Holstein,
Germany,
- to identify differences in medical care with high prognos-
tic relevance, factors associated with them and the extent
to which these differences contribute to the outcome,
- to compare reported information on medical care with
other data pools and evidence-based reference data
(guidelines, indicators of quality).
The reasons for including patients with breast or prostate
cancer and malignant melanoma of the skin can be out-
lined as follows: the present study is intended to cover
both sex-specific tumours and a type of cancer which
occurs in both sexes. Priority was given to prevalent can-
cers and tumours of high public interest. Malignant breast
and prostate neoplasms are the most frequent tumours
among Germans. The incidence of malignant melanoma
of the skin was always comparably small until recently.
Over the past decades, the incidence of malignant
melanoma has been on the rise, increasing the level of
professional and public interest in this type of cancer. For
the sake of the survey, the selected tumours should be
growing slowly, allowing for a time delay of about 18
months between diagnosis and survey contact. To prevent
possible biases in recruitment due to incomplete registra-
tion [21,22], registration procedure had to be completed
by the time of scientific contact.
Research on medical care makes often use of secondary
data. However, the definition of the source population
appears to be a major problem in studies with secondary
data [15,18,23]. The OVIS-study used the population-
based Cancer Registry of the state Schleswig-Holstein as a
data source for recruitment and comparison to the general
population (estimation of representativeness).
The data of cancer patients notified to the Cancer Registry
was available on request for scientific purposes. The OVIS
study had access to both personal and epidemiological
data for all patients. Information was drawn from two
data sources in the OVIS-study – the Cancer Registry and
the questionnaire consisting of a series of questions on
received oncological care.
The present paper gives a short account of the basic data
and answers the following questions:
- Is it possible to draw a population-based representative
sample by recruiting cancer patients for health care
research from cancer registries?
- In which way and to what extent do participants of such
studies differ in the most important epidemiological char-
acteristics from the source population?
Excursus: Healthcare system and cancer registration in 
Germany
For a better comprehension of this study, it would be
appropriate to briefly review the healthcare system, data
privacy protection and cancer registration in Germany.
A societal consensus about how data privacy should be
protected is reflected in the legal system (right to informa-
tional self-determination). Storage of personal data and
especially linking of personal data from multiple sources
requires informed consent. German citizens are not
assigned a lifelong social insurance number or a central
population registry number that could be used to estab-
lish a link to the information they had provided, which
renders it difficult to carry out a population-based analy-
sis.
The German healthcare system is highly decentralised:
- federal structures (sixteen states having sole responsibil-
ity with different legislation)
- widely independent sectors (inpatient, outpatient, spe-
cialists in private practice) with self-administration
- separate sectors of reimbursement – statutory (about 250
statutory health insurance companies) and private insur-
anceBMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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There is no systematic exchange of data and no linking
between the different sectors, neither on an individual nor
on a population-based level. (Full information on treat-
ment is stored in the health insurance data set – accessible
to the insured person only – however, person profiles vary
significantly from one insurance company to another.)
Although cancer registration has a long tradition in some
parts of Germany, the mandatory nationwide registration
started with the German Cancer Registry Act between
1995 and 1999. All physicians in most states are required
to submit a notification to the Cancer Registry of all can-
cer cases that come to their attention. Cancer registration
in Germany is conducted by eleven regional registries reg-
ulated by sixteen different cancer registry laws of the fed-
eral states. In compliance with data privacy regulations,
most registries are divided into two registration offices.
The Data Collection Office receives data on cancer
patients and is allowed to keep their names, addresses and
unique patient numbers, but has to delete medical data.
The Data Analysis Office receives anonymous data (no
personal data, but a unique number) coupled with medi-
cal data from the Data Collection Office. Thus, personal
and medical data are kept separately. Linking identifiable
individuals to the information they had provided is only
possible in case of an informed consent by patient.
Methods
The OVIS study was designed as a population-based state-
wide cohort study of patients diagnosed with cancer in the
period between 2001 and 2003 and reported to the Can-
cer Registry between January 2002 and July 2004, the pri-
mary diagnostic codes being C43, C50 and C6 in the ICD-
10 classification. The study protocol was approved by the
ethics committee of the University of Luebeck (reference
no. 01–010). All subjects agreed to participate on a volun-
tary basis and gave their written informed consent.
Recruitment
Under state law of Schleswig-Holstein, all instant cancer
cases are subject to mandatory notification. Every general
practitioner, physician or pathologist in attendance on a
person with clinical evidence of cancer is required to
report newly diagnosed cancers to the Cancer Registry.
The cancer patients about whom they must report have no
choice, as the principles of consent does not apply accord-
ing to law. However, if notification is required, the patient
can choose between notification by name and notifica-
tion by code. In the first case, records of cancer are kept by
name in the Cancer Registry. This implies a general con-
sent to be approached to participate in potential research
projects. The second choice is coded cancer reporting.
Coded identifiers are appended to clinical and personal
data (age, sex, place of residence) provided by the patient,
making the patient anonymous. All cases reported solely
by pathologist belong to this group.
Patients notified by name to the Cancer Registry, who
were assumed to have agreed to participate, were con-
tacted via mail. The invitation included a detailed descrip-
tion of the research project, a study questionnaire, a
patient's declaration to participate, a declaration form
allowing the study researchers to contact the general prac-
titioner (GP) and a pre-addressed stamped return enve-
lope. Non-respondents were sent a maximum of two
reminders (week 4 and week 8 from first mailing). If these
attempts did not result in a response, vital status or
address were ascertained at the Residence Registration
Office. Recruitment mailings were done in four waves at
intervals of sixth months between 2003 and 2005. Data
were requested from the Cancer Registry four times – once
for each wave. This was done to prevent major differences
in the time span between diagnosis and contact and to
achieve efficient data query from the Cancer Registry.
The following are the criteria for inclusion:
- first tumour diagnosis in the period from 2001–01 to
2004–04
- age in the range of 18 to 85 years at diagnosis
- residence in Schleswig-Holstein at diagnosis
- the ICD-10 primary tumour site codes C43, C50 or C61
- patient is female (in case of breast cancer)
Exclusion criteria used in selection of research subjects:
Deceased cases were retrospectively excluded from the
study and were not part of the source population (cohort
A in figure 1). The vital status of non-eligible patients
(cohort B in figure 1) was partly unknown. Patients noti-
fied by death certificates only were excluded (deceased
patients). Subjects may only be enrolled in one cancer site
of the study: participants qualified for one cancer site were
excluded from participation in other cancer sites.
Cohorts
Several cohorts have evolved reflecting different ways of
notification to the Cancer Registry and willingness to par-
ticipate (figure 1). Of all patients kept in the Cancer Reg-
istry those patients were excluded who do not meet the
inclusion criteria. The remaining patients form the source
population (cohort A in figure 1). This cohort divides into
the cohort of patients who chose notification by code (in
the following referred to as non-eligible patients, cohort B
in figure 1) and the cohort reported by name (cohort C –BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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referred to as eligible patients). The patients of this latter
cohort received the questionnaire. Cohort C was made up
of non-respondents (cohort E) and patients who returned
the questionnaires (referred to as participants – cohort F).
Non-eligible patients (cohort B) and non-respondents
(cohort E) form the cohort of non-participants (cohort D)
– these were the patients who did not complete the ques-
tionnaire. For all cohorts, a relatively small epidemiologi-
cal data set exists in the Epidemiological Cancer Registry
[24]. The data set includes information on diagnosis
(ICD-10 coded), histology, tumour stage, age, gender,
place of residence, therapies (yes, no), and some other.
The above mentioned epidemiological data from the Can-
cer Registry were used to compare different cohorts.
To assess the representativeness of participants, we com-
pared them to non-participants (cohort D consisting of
non-respondents and patients with notification by code)
and the source population (cohort A).
Rates and comparisons
Patients had to decide on study participation twice. At
notification to the Cancer Registry patients can give a gen-
eral consent to be invited to participate in research
projects. All patients who refused consent and those noti-
fied only by pathologist (pathologists can not ask for con-
sent) cannot decide on their cooperation in the second
phase, the second phase being participation in the OVIS
study. To account for different decision levels, we intro-
duced two participation rates. The study size is the ratio of
participants to the source population in percent (cohort F/
cohort A * 100). This ratio can be interpreted as the size
of a sample that is activated by recruiting cancer patients
from a cancer registry.
Cohorts of the study Figure 1
Cohorts of the study.BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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The second rate is the ratio of participants to all eligible
patients (cohort F/cohort C * 100). This rate can be inter-
preted as recruitment efficiency [25]. Both rates have to be
stratified by sex (in case of C43) and age (all entities). Age
was dichotomised by the median age of the source popu-
lation (cohort A) for each type of cancer – with "young"
meaning an age of less than or equal to the median age
and "old" meaning an age above the median age.
Decisive with respect to possible bias is the cooperative-
ness of patients. The existence and (if necessary) the
nature of differences between participants (cohort F) and
non-participants (cohort D) has been checked. Partici-
pants (cohort F) were compared to non-participants
(cohort D) to assess the representativeness of the partici-
pating cohort (selection bias). A comparison of partici-
pants to the source population was not done by reason
that the cohort of participants is not independent from
the source population. We used only the epidemiological
data from the Cancer Registry for comparison because this
data was available for all cohorts. Information provided
in the questionnaires were not used to improve data
stored in the Cancer Registry, such an improvement could
generate a bias since data improvement was not possible
for cohort D.
We have intentionally refrained from comparison of par-
ticipants (cohort F) to non-respondents (cohort E)
because the number of non-respondents was small com-
pared to the number of non-eligible patients (cohort B),
thus shifting away from the focus on representativeness.
Questionnaire and data handling
Depending on the cancer site, the questionnaire included
about 60 questions and requested information on diagno-
sis, therapy, quality of life, rehabilitation, post-operative
treatment, patient's information and socioeconomics.
Data obtained from research participants were stored in
an Access database. To protect the confidentiality of the
information, personal data were separated from study
data and password-protected.
Data entry was done by medically trained staff. Range
(validity) and logical (plausibility) checks were per-
formed routinely at data entry by the computer program.
Any inconsistency or invalid information was verified or
corrected manually by data entry staff. Any implausibility
within the questionnaires caused by the respondent was
corrected by standard procedures (e.g. The questionnaire
asked for duration in days and the patient answered in
years. We calculated the days.). The quality of data entry
was checked by double data entry for a control sample
including 5% of all data entries with 179 data fields per
single data set. The overall proportion of errors was less
than 1%.
Used scores, categories and quality of life
Social status was determined by using a three level model
appropriate for Germany [26]. It is an additive sum score
made up of three coded items (highest school leaving cer-
tificate, occupational status and household net income).
Missing values were substituted by the mean of the two
other items. If there was more than one missing value,
social status was not computed. The score differentiates
between three social levels. It can be considered a simpli-
fied form of the frequently used Winkler-Index [27] with
comparable results in the distribution.
The spatial aspect was a further factor to be considered in
the quality of medical care service. Supply may possibly
differ between rural and urban areas. Therefore, compari-
sons were made between these two categories, which are
defined by regional planning state law [28].
The global quality of life/health status was assessed using
the EORTC QLQ-C30 [29]. According to the EORTC
guidelines, the score was transformed linearly and stand-
ardized to a scale ranging from 0 to 100.
Statistical methods
In the present paper, descriptive statistics (absolute and
relative frequencies, mean and median values as well as
standard deviations) is used to summarize the data. The
Chi-Square- and Mann-Whitney U-tests were conducted
to analyse differences between participants (cohort F in
figure 1) and non-participants (cohort D).
A multivariate approach was applied to exclude interac-
tions between the variables used in the univariate analy-
sis. The following independent variables were included in
a binary logistic regression model: surgery [yes, no,
unknown], T-category [T1, T2, T3, T4, unknown], spatial
category [rural, urban, unknown], age [years], sex [male,
female] in case of C43 and hormone therapy [yes, no,
unknown] in case of C61. The outcome variable was the
variable participant [yes, no]. All cases that were submit-
ted to the Cancer Registry solely by pathologists (C43: 28
cases, C50: 228 cases, C61: 362 cases) had to be excluded
from the multivariate analysis because of missing clinical
information.
Results
In the period from January 2002 to July 2004, a total of
12,586 patients with breast cancer (5,800; 46.1%), pros-
tate cancer (5,185; 41.2%) and malignant melanoma
(1,601; 12.7%) were reported to the Cancer Registry of
Schleswig-Holstein. 1,097 patients (8.7%) failed to meet
the inclusion criteria and had to be excluded from the
study. The excluded patients were 98 cases (6.1%) of
reported malignant melanoma, 552 cases (9.5%) of breast
cancer, and 447 cases (8.6%) of prostate cancer.BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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The remaining 11,489 patients (91.3% of all notifica-
tions) met the inclusion criteria and represent the source
population (cohort A in figure 1) of the study. Of those
patients who remained in the study, 5,354 patients
(46.6%) were eligible for scientific contact (cohort C in
table 1).
The study size – as measured by the ratio of participants
(cohort F) to the source population (cohort A) – was
37.3% over all tumour entities based on 4,285 completed
self-administered questionnaires. Table 1 differentiates
the results by the three analyzed tumour entities. Stratifi-
cation by sex was only appropriate for malignant
melanoma: The study size was 42.9% for men and 38.6%
for women (p = 0.093). After stratification by sex and age,
the study size was estimated at 38.5% for younger (< = 58
years) and 46.0% for older (59 years and older) men (p =
0.056) and at 39.0% for younger and 38.0% for older
women (p = 0.776). In breast cancer patients, the study
size amounted to 41.2% for younger women (< = 61
years) and 32.2% for older women (62 years and older) (p
< 0.001). The study size was 42.7% for younger men (< =
68 years) and 30.4% for older men (69 years and older)
(p < 0.001) in prostate cancer patients.
The recruitment efficiency rate – defined as the ratio of
participants (cohort F) to all eligible patients (cohort C) –
over all tumour entities reached 80.0%. The recruitment
efficiency rate was not different for the sex-specific
cohorts. After adjustment for sex and age, the recruitment
efficiency rate in melanoma patients was 78.5% for
younger and 80.6% for older men (p = 0.644) as well as
82.5% for younger and 76.3% for older women (p =
0.121). The recruitment efficiency rate in breast cancer
patients was 85.3% for younger women and 76.5% for
older ones (p < 0.001).
In patients with prostate cancer, the recruitment efficiency
rate for younger men was 83.3% and 71.6% for older
patients, respectively (p < 0.001).
Characteristics of 4,285 study participants
Table 2 summarises the characteristics of 4,285 study par-
ticipants including sociodemographics (age, social status,
spatial category) and main aspects of medical care (diag-
nosis, therapy, rehabilitation, global health status). The
median age of patients with malignant melanoma dif-
fered between the genders, men being on average 62.5
and women 54.0 years of age (p < 0.001). 48.8% of the
population of Schleswig-Holstein live in rural and 51.2%
in urban areas. This distribution is also present in
melanoma and breast cancer patients. Only participants
with prostate cancer were more likely to live in an urban
area. The median time from diagnosis to survey contact in
the context of the OVIS study was 396 days for C43, 525
days for C50 and 481 days for C61, respectively.
Non-respondents (cohort E)
A total of 1,069 patients who were contacted by mail
chose to exclude themselves from the proposed study
(cohort E in figure 1). The non-respondents were evenly
distributed between the three cancer entities accounting
for 20% of all eligible patients (table 1). About a quarter
of these patients simply did not respond, another 59%
returned the questionnaire uncompleted without specify-
ing reasons for not completing the questionnaire and
about 5% did not answer for age or health reasons. For
3.6% of all eligible participants, the valid address could
not be obtained.
Reasons for non-participation varied only little between
the cancer sites. For prostate cancer, we found with 4% a
higher value for the category "The study is too complex"/
Table 1: Case numbers of the cohorts in the study
Melanoma Breast cancer Prostate cancer
N% N % N %
Basic population
(cohort A)
1,503 100 5,248 100 4,738 100
non eligible patients
(cohort B)
741 49.3 2,882 54.9 2,512 53.0
eligible patients
(cohort C)
762 50.7 2,366 45.1 2,226 47.0
Participants
(cohort F)
608 40.5 *
[79.8]
1,927 36.7 *
[81.4]
1,750 36.9 *
[78.6]
Non-respondents
(cohort E)
154 10.2
[20.2]
439 8.4
[18.6]
476 10.0
[21.4]
Non-participants
(cohort D)
895 59.5 3,321 63.3 2,988 63.1
* The value without parenthesis describes the study size (Percentage of the participants to the basic population). The value with parenthesis 
describes the recruiting efficiency proportion (Percentage of the participants to the eligible patients)BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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"not convinced of the sense of the study" (3.2% over all
three groups). 3.2% of non-respondents with prostate
cancer denied their cancer disease (C50: 0.5%, C43:
1.3%) despite having given a written consent for notifica-
tion by name to the Cancer Registry. About 1.1% of non-
respondents with breast cancer did not want to be
reminded of the disease and declined their participation.
The same reason was found in one melanoma patient but
seemed to be completely irrelevant for all prostate cancer
patients.
Comparison of participants to non-participants
Survey participants (cohort F, figure 1) were compared to
non-participants (cohort D) to assess the representative-
ness of the sample. Figure 2 illustrates the distribution of
age in the above specified cohorts with respect to the three
cancer entities.
After stratification by sex, no significant differences were
found in the age distribution of melanoma patients. The
difference in the median age between participants and
non-participants was a little higher for men (62.5 years vs.
60.0 years; p = 0.141) than for women (54.0 years vs. 53.5
years; p = 0.878).
Table 3 summarises further characteristics of participants
(cohort F), non-participants (cohort D), and the source
population (cohort A). More women than men were reg-
istered with malignant melanoma, but men were more
likely to be respondents than non-respondents (46.1% vs.
41.7%).
A multivariate analysis was performed for each tumour
entity. The results of multivariate analyses were found to
be in agreement with the univariate results (table 3) with
Table 2: Characteristics of the participants
Melanoma Breast cancer Prostate cancer
Variable (N = 608) (N = 1,927) (N = 1,750)
Age at first diagnosis [yrs]
Mean ± SD 55.5 ± 15.7 58.8 ± 11.3 66.9 ± 7.0
Median 59 60 66
Sex [%]
Male 46.1 -- 100
Female 53.9 100 --
Social level [%]
Lower 12.4 15.6 14.0
Middle 65.0 67.9 63.4
Upper 22.6 16.5 22.6
(N = 589) (N = 1,851) (N = 1,718)
Spatial category [%]
Rural 48.4 48.6 56.3
Urban 51.6 51.4 43.7
Time between initial diagnosis and questioning [%]
12 months or less 42.9 18.2 23.6
12 to 24 months 43.4 59.5 58.7
more than 24 months 13.7 22.3 17.7
Health insurance [%]
Private 7.7 4.1 9.8
Statutory 92.3 95.9 90.2
(N = 534) (N = 1,743) (N = 1,456)
Living with spouse [%] 79.4 73.5 89.5
(N = 606) (N = 1,921) (N = 1,737)
Detection of cancer [%]
By myself or by my partner 60.1 56.9 9.1
By a medical examination 32.8 39.2 82.3
Other 7.1 3.9 8.6
(N = 594) (N = 1,914) (N = 1,713)
Surgery [%] 99.3 98.4 70.4
(N = 602) (N = 1,918) (N = 1,657)
Attendance to a rehabilitation [%] 6.4 52.3 45.1
(N = 598) (N = 1,871) (N = 1,647)
Global health status (QLQ-C30)
Mean ± SD 74.1 ± 22.9 65.5 ± 22.4 68.4 ± 20.8
Median 83.3 66.7 66.7
(N = 593) (N = 1,866) (N = 1,704)BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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just one exception – the item "surgery" for prostate cancer
was not included in the final model.
Deceased patients
Patients deceased by the time of survey contact were
excluded from the OVIS-study in agreement with the
exclusion criteria. The vital status of patients with anony-
mous notification (cohort B) to the Cancer Registry was
unknown, with the consequence that possibly dead could
not be excluded from cohort B. In consideration of repre-
sentativeness issues, some epidemiological characteristics
of patients notified by name and deceased by the time of
survey (and then excluded) are given in the following.
Seventeen patients with malignant melanoma died in the
time span between diagnosis and survey contact. Their
median age at primary diagnosis was 73 years. The 116
deceased patients with breast cancer (median age 63.5
years) showed the following distribution of the T-cate-
gory: T1 = 22.4%, T2 = 35.3%, T3 = 13.8%, T4 = 19.8%
and unknown = 8.6%. The proportion of operated
patients was 81.9%. Deceased prostate cancer patients (n
= 109) had a median age of 72 years (T1 = 20.2%, T2 =
30.3%, T3 = 15.6%, T4 = 8.3% and unknown = 25.7%),
24.8% were operated (not operated = 32.1%, unknown =
43.1%). A hormone therapy was received by 62.4% (no
hormone therapy = 12.8%, unknown = 24.8%).
Discussion
The aim of the OVIS-study is the presentation and evalua-
tion of the medical care situation of cancer patients diag-
nosed with malignant melanoma, breast and prostate
cancer. In this paper, the data was critically analyzed in
terms of representativeness. Possible biases (e.g. selection
bias) were identified and have to be considered when
evaluating the results of further analyses.
Study approach
The objective of the OVIS-study is to survey all patients
with the neoplasms in question residing in the study area.
The population-based approach gives a better guarantee
Age distribution of the study cohorts Figure 2
Age distribution of the study cohorts. Significance of the difference between participants (cohort F) and non-participants 
(cohort D): Melanoma: p = 0.341; breast cancer: p < 0.001; prostate cancer: p < 0.001.
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Table 3: Comparison of epidemiological items between the study cohorts/representativeness
Characteristics Basic population 
(cohort A)
Respondents (cohort F) Non-participants 
(cohort D)
p-value for difference 
between cohort F & D
%%%
Melanoma
N 1,503 608 895
Sex 0.093
Male 43.4 46.1 41.7
Female 56.6 53.9 58.3
Surgery 0.877
Yes 87.9 88.3 87.6
No 0.4 0.3 0.4
Unknown 11.7 11.3 12.0
T-category 0.208
T1 30.9 30.9 30.8
T2 11.8 10.7 12.5
T3 8.4 9.0 8.0
T4 2.7 1.6 3.4
Unknown 46.2 47.7 45.3
Spatial category 0.261
Rural 46.6 48.4 45.4
Urban 53.4 51.6 54.6
(N = 1,500) (N = 892)
Breast cancer
N 5,248 1,927 3,321
Surgery < 0.001
Yes 88.8 93.2 86.3
No 1.9 0.5 2.8
Unknown 9.2 6.3 10.9
T-category < 0.001
T1 48.4 53.8 45.3
T2 34.4 34.6 34.3
T3 4.8 4.5 5.0
T4 6.9 3.4 9.0
Unknown 5.4 3.7 6.4
Spatial category < 0.001
Rural 52.1 48.6 54.2
Urban 47.9 51.4 45.8
(N = 5,228) (N = 3,301)
Prostate cancer
N 4,738 1,750 2,988
Surgery < 0.001
Yes 46.3 56.4 40.5
No 19.8 17.6 21.0
Unknown 33.9 26.0 38.5
Hormone therapy < 0.001
Yes 31.5 28.2 33.4
No 28.2 34.3 24.6
Unknown 40.3 37.4 42.0
T-category < 0.001
T1 15.9 15.0 16.4
T2 39.0 45.8 35.0
T3 22.8 28.5 19.5
T4 1.9 1.5 2.2
Unknown 20.4 9.3 27.0
Spatial category 0.124
Rural 54.8 56.3 54.0
Urban 45.2 43.7 46.0
(N = 4,718) (N = 2,968)BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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that the data is representative and that no systematic
exclusions of whole patient groups take place. About
5,000 patients participated in the OVIS-study, thus result-
ing in adequate numbers for subgroup analysis. Subgroup
analyses were essential for description and analysis of
medical care and provided answers to questions like:
"Does the place of residence determine how medical care
is delivered?" and "Do patients utilize medical care differ-
ently and what is the outcome?"
Records of cancer from the Epidemiological Cancer Regis-
try were used as a data source for patient recruitment. Two
reasons were decisive in this choice. Firstly, the Cancer
Registry is the most complete data source for population-
based research. More than 95% of all expected cases of the
chosen cancer sites are registered. All other possible data
sources (e.g. clinical cancer registries, doctors or unsys-
tematic questionings) are less complete, suggesting a
stronger selection bias. Secondly, the already existing epi-
demiological dataset was available. This dataset is existent
not only for patients reported by name to the Cancer Reg-
istry but for all patients included in the Registry, which
allows comparison between participants and non-partici-
pants as well as between participants and the source pop-
ulation. Whereby not only can the representativeness of
the sample be estimated, but possible biases can be
detected and described in terms of strength and direction.
One of the arguments against the use of cancer registry
data for patient recruitment is a time lag of 12 to 18
month between first diagnosis and contact: The delay is
due to untimely notification and high processing time
(data entry, enquiries, record linkage etc.) inside the Can-
cer Registry. The counter-argument is that other prepon-
derate problems (e.g. incomplete registration, missing
reference population data) might exist, even if other data
sources did not have this problem. Two effects result from
this time-lag. On the one hand, a survival cohort is ques-
tioned – given that the cancer sites of interest have a high
relative survival rate (> 90% one-year-survival, [30]), that
bias should be small. On the other hand, recall-bias might
occur due to the time-lag. However, cancer is thought to
be a very traumatic experience that it can be assumed that
patients remember diagnosis, therapy and aftercare very
well. Few comparative data exist to corroborate this
assumption [31-33]. For a small subsample (56 cases) of
the OVIS-study, the same data were collected during the
hospital stay and again 12 month later, which allowed
validity analysis. The analysis showed an excellent con-
cordance between information given during initial hospi-
tal stay and 12 months after diagnosis [34]. A smaller
time-lag, attributable to early notification by dermatolo-
gists in the study region, was observed for malignant
melanoma.
Representativeness
High response rate is a major determinant of representa-
tiveness. The recruitment efficiency rate of about 80%
achieved in the OVIS-study is adequate and comparable
to other studies. It happens to be a little higher than in the
investigation of breast cancer patients based on SEER-data
that was conducted by Janz et al. [35], and higher than
Karakiewicz et al. [36] reported for prostate cancer
patients from Quebec, Canada. However, it is lower than
response rates reported for patients with breast cancer and
melanoma by Lehto et al., based on hospital data in Fin-
land [37]. Arndt et al. from Saarland, Germany, found
similar response rates for patients with colorectal cancer
[38] and breast cancer [39].
The principal question addressed is whether there are dif-
ferences between participants (cohort F) and non-partici-
pants (cohort D). Consideration of representativeness was
a major factor motivating this comparison. To evaluate
representativeness, univariate and multivariate
approaches were employed to analyze the epidemiologi-
cal variables. Just minor differences were observed in the
results of both approaches (see below).
There is another important aspect to consider when eval-
uating representativeness. The cohort of participants is a
pure survivor cohort, while deceased persons are possibly
included in the non-eligible group. Vital status informa-
tion could only be obtained for patients who were
reported by name to the Cancer Registry – according to
the exclusion criteria deceased patients were excluded
from the OVIS-study. Hence, patients of the cohorts E and
F were alive at the time of questioning. In case of notifica-
tion by code to the Cancer Registry, vital status could not
be determined with certainty (exceptions are cases noti-
fied by death certificate only – the so called death-certifi-
cate-only cases). It might be the case that some
anonymously notified patients deceased in the period
between diagnosis and survey contact. Deceased (and
excluded) patients reported by name were older and had
a higher tumour stage compared to respondents. The
cohort of non-participants (cohort D) is composed of
about 15% non-respondents (cohort E, deceased patients
excluded) and about 85% non-eligible patients (cohort B,
including an unknown number of deceased patients).
Under the well-founded assumptions that cohort B
included some (possibly the same proportion of)
deceased patients and that these might have similar char-
acteristics as the excluded deceased patients (older, higher
tumour stage), it is obvious that the detected and shown
differences between participants and non-participants
might be statistically more preponderant than in (clinical)
reality.BMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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Knowing the vital status of all patients would have possi-
bly leaded to minor differences between the cohorts.
However, the relevance of this effect is different for the
cancer sites in question. It appears to be less pronounced
in patients with malignant melanoma for the reason of
lower median age and survival probability associated with
it. It is most preponderant in prostate cancer patients due
to higher age and comorbidities.
Malignant Melanoma
Participants with malignant melanoma were very similar
to the source population, with a difference of 2.5 years in
median age, men deviating more strongly from the
median than women. It can be assumed that a slightly
higher response rate in older men (recruitment efficiency
rate: 80.6%) brought about this difference. Why older
men were more willing to participate remains unclear, but
there might be an influence of the variables "living with
spouse" and/or "education". On the whole, the observed
differences are so small that participants with malignant
melanoma in the OVIS-study seem to be a representative
sample of the source population.
Breast cancer
In patients with breast neoplasm, participants and non-
participants differed statistically significantly in every
demographic category used to evaluate representative-
ness. Whether these differences were clinically relevant
(leading to an unrepresentative sample) has to be exam-
ined. Participants were on average 2 years younger than
non-participants, which have to be considered in the
interpretation of results. No relevant and systematic influ-
ence of age difference on the results of the study could be
observed. The variable 'age' is regarded as a confounder in
most of the statistical analyses. The same is true for the
variable 'tumour stage' (T-category). Here again, the dif-
ferences are statistically significant. There were nearly no
differences found for T2- and T3-category, but participants
appeared to have more frequently T1-tumours and less
frequently T4-tumours. In further analyses, the T-category
will be used as a confounder. In reality, the difference will
be less pronounced as expected due to the survival effect
(see above). The ratio of deceased (excluded) patients (all
notified by name) to all eligible patients (cohort C) was
about 5% (116 to 2366+116). Deceased patients were on
average 3,5 years older than participants and 1,5 years
older than non-respondents and had a considerably
higher proportion of T3 and T4 tumours.
As shown in Table 3, nearly all patients had undergone
surgery. Due to the study size the observed difference of
7% is statistically significant. This difference can hardly be
regarded as clinically relevant as most patients (~90%)
were operated. It cannot be, however, ignored in specific
analyses. The relevance of the variable 'spatial category'
for the representativeness of the sample can not be finally
evaluated here. The difference is less pronounced but sig-
nificant. It could be relevant if substantial regional dis-
tinctions were analysed between rural and urban areas.
Initiated but not finished analyses do not show such
divergences between rural and urban areas. By large, the
sample can be regarded as representative with a few limi-
tations that can be controlled (age, tumour stage).
Prostate cancer
Participants with prostate cancer were on average four
years older than non-participants. This is a relatively con-
siderable discrepancy, given that the above described sur-
vival effect might have a major impact on this cancer site
because of the median age of these patients (the median
age in the source population was 68 years). Therefore, the
real difference should be less pronounced. The ratio of
deceased (excluded) patients (all notified by name) to all
eligible patients (cohort C) was nearly 5%. Deceased
patients were on average 6 years older than participants
and 3 years older than non-respondents. They had a
higher proportion of T1 and T4 tumours. After exclusion
of deceased non-participants (which was not possible,
though), the proportion of T4 tumours in non-partici-
pants would have been smaller. There is a considerable
difference in the category "unknown tumour stage"
between participants and non-participants (3 times
higher), which can be ascribed to the chosen way of noti-
fication. About 12% of non-participants were notified
only by laboratory. In such cases, the tumour stage
remains largely unknown. Notification by name only by
laboratory is impossible. There is no contact to the
patient. Notification by name requires necessarily notifi-
cation by clinician. If only cases with known tumour stage
were analyzed, under the assumption that unknown cases
were not biased, the differences in the tumour stage distri-
bution between participants and non-participants would
be less pronounced. Similarly, the variables "surgery" and
"hormone therapy" differed between both cohorts. It
seems that operated patients were more willing to partici-
pate in the study than patients treated with a hormone
therapy. Simply said, patients treated curatively tend to be
operated more often and patients treated palliatively were
likely to receive a hormone therapy – both are correlated
with age and tumour stage. The conclusion to be drawn,
therefore, is that the kind of treatment has to be consid-
ered in statistical analyses. On the whole, the sample
reached a high degree of representativeness for the source
population.
The assessment of representativeness in terms of socio-
economic criteria remains incomplete since these varia-
bles are not part of the Cancer Registry. One of the objec-
tives of the OVIS-study is to determine whether variables
like "living with spouse", "social level", "kind of healthBMC Cancer 2008, 8:311 http://www.biomedcentral.com/1471-2407/8/311
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insurance" have any effect on medical care in patients
with malignant neoplasms.
Conclusion and prospects
The OVIS-study is one of the largest population-based
studies focussing on the situation of medical care of can-
cer patients in Germany. The Epidemiological Cancer Reg-
istry as a data source for recruiting proved to be useful to
estimate the extent and nature of bias effects. It could be
shown that there were just minor differences between par-
ticipants and non-participants in terms of age and tumour
stage distribution. Hence, both factors allow to be con-
trolled for in further multivariate analyses. It is intended
to perform a follow up survey in two years.
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